EBNA2 Gene Variants as MS Risk Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods struggle to explain the pathogenetic mechanisms behind the association between the ubiquitous Epstein Barr virus (EBV) and multiple sclerosis (MS), particularly due to the discrepancy between the virus's widespread infection and limited MS prevalence, and lack effective means to identify at-risk individuals or therapeutic targets.
Innovation Solution
The identification of specific gene variants of the Epstein Barr nuclear antigen 2 (EBNA2) protein, particularly the 1.2 subtype, as biomarkers for predicting MS risk and therapeutic targets, using nucleic acids, mRNAs, or proteins with specific amino acid substitutions, enabling non-invasive and cost-effective screening and diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If whole viral genome sequencing is used to study EBV variants, then comprehensive genetic information is obtained, but methodological difficulties and complexity increase
Solution Approach 1:
The patent divides the complex task of whole genome sequencing into a focused candidate-gene approach, specifically targeting the EBNA2 gene region. This segmentation allows studying EBV variants associated with MS without the complexity of sequencing the entire viral genome, while still obtaining the specific genetic information needed to identify risk variants.
Solution Approach 2:
The patent extracts and focuses on the specific EBNA2 gene region from the complete EBV genome. By taking out only the relevant candidate gene that shows association with MS, the method obtains the necessary genetic information while avoiding the methodological difficulties of comprehensive genome sequencing.
2Measurement precision
If specific gene variants are identified as biomarkers, then diagnostic capability is improved, but the discrepancy between ubiquitous virus infection and limited MS prevalence remains unexplained
Solution Approach 1:
The patent applies local quality by identifying specific amino acid variants (K245E and R267H) within the EBNA2 gene that are locally associated with MS risk. Rather than treating the entire virus as uniform, the method identifies specific local genetic variations that distinguish pathogenic strains from benign infections, thereby explaining the discrepancy between ubiquitous infection and limited disease prevalence.
3Adaptability or versatility
If anti-EBV substances are used for treatment, then therapeutic approach is provided, but lack of specific target identification limits effectiveness
Solution Approach 1:
The patent identifies asymmetric differences in the EBNA2 gene sequence between MS-associated strains and control strains, specifically the K245E and R267H variants. These asymmetric genetic differences provide specific molecular targets for therapeutic intervention, allowing development of targeted anti-EBV substances that specifically address the pathogenic variants rather than treating all EBV infections uniformly.
Data Source
Figure 1
AI summary
The present invention relates to a nucleic acid coding for a variant of the Epstein Barr nuclear antigen 2 (EBNA2) for use as a biomarker for predicting the risk of developing multiple sclerosis and/or for screening and/or for the diagnosis and/or prognosis of multiple sclerosis, and to an in vitro method for predicting the risk of developing and/or for screening for multiple sclerosis and/or for the diagnosis and/or prognosis of multiple sclerosis in a subject, comprising the detection of the presence of said nucleic acid.